about
PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases.Surface changes and polymyxin interactions with a resistant strain of Klebsiella pneumoniae.Aldehyde-sequestering drugs: tools for studying protein damage by lipid peroxidation products.Hyaluronic Acid Molecular Weight Determines Lung Clearance and Biodistribution after Instillation.New developments in dry powder pulmonary vaccine delivery.Targeting the lymphatics using dendritic polymers (dendrimers).Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties.Association of chemotherapeutic drugs with dendrimer nanocarriers: an assessment of the merits of covalent conjugation compared to noncovalent encapsulation.Nano-chemotherapeutics: maximising lymphatic drug exposure to improve the treatment of lymph-metastatic cancers.From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity.Conjugation of 10 kDa Linear PEG onto Trastuzumab Fab' Is Sufficient to Significantly Enhance Lymphatic Exposure while Preserving in Vitro Biological Activity.Disposition and safety of inhaled biodegradable nanomedicines: Opportunities and challenges.Molecular weight (hydrodynamic volume) dictates the systemic pharmacokinetics and tumour disposition of PolyPEG star polymers.PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance after subcutaneous administration.Optimal PEGylation can improve the exposure of interferon in the lungs following pulmonary administration.Methotrexate-conjugated PEGylated dendrimers show differential patterns of deposition and activity in tumor-burdened lymph nodes after intravenous and subcutaneous administration in rats.Chaperone heat shock protein 90 mobilization and hydralazine cytoprotection against acrolein-induced carbonyl stress.Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models.Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker.The Pharmacokinetics and Biodistribution of a 64 kDa PolyPEG Star Polymer After Subcutaneous and Pulmonary Administration to Rats.An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration.A Comparison of the Pharmacokinetics and Pulmonary Lymphatic Exposure of a Generation 4 PEGylated Dendrimer Following Intravenous and Aerosol Administration to Rats and Sheep.PEGylated interferon displays differences in plasma clearance and bioavailability between male and female mice and between female immunocompetent C57Bl/6J and athymic nude mice.Spray-Dried Influenza Antigen with Trehalose and Leucine Produces an Aerosolizable Powder Vaccine Formulation that Induces Strong Systemic and Mucosal Immunity after Pulmonary Administration.PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats.The contribution of the metabolite p-hydroxyamphetamine to the central actions of p-methoxyamphetamine.A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems.Protein adduct-trapping by hydrazinophthalazine drugs: mechanisms of cytoprotection against acrolein-mediated toxicity.Strong protein adduct trapping accompanies abolition of acrolein-mediated hepatotoxicity by hydralazine in mice.The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules.Reactivity of hydrazinophthalazine drugs with the lipid peroxidation products acrolein and crotonaldehyde.PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin.Partly-PEGylated Poly-L-lysine dendrimers have reduced plasma stability and circulation times compared with fully PEGylated dendrimers.Practical lessons in murine thoracic lymph duct cannulations: observations in female and male mice across four different strains that impact on "cannulatability".Differences in lysine adduction by acrolein and methyl vinyl ketone: implications for cytotoxicity in cultured hepatocytes.Impact of surface derivatization of poly-L-lysine dendrimers with anionic arylsulfonate or succinate groups on intravenous pharmacokinetics and disposition.Distribution of therapeutic proteins into thoracic lymph after intravenous administration is protein size-dependent and primarily occurs within the liver and mesentery.Microfluidic preparation of drug-loaded PEGylated liposomes, and the impact of liposome size on tumour retention and penetration.Influence of Size and Shape on the Biodistribution of Nanoparticles Prepared by Polymerization-Induced Self-Assembly.A comparison of the lung clearance kinetics of Solid lipid nanoparticles and Liposomes by following the 3H-labelled structural lipids after pulmonary delivery in rats.
P50
Q33619866-1E4D13E8-7BE3-4430-AA20-3185673927BDQ34565093-14A9EED1-F2B6-44C8-9621-0B8554A592F5Q35035514-279C8653-C58E-4A8A-A44A-FB16F98E8743Q37545580-2B9BDDD5-0DF4-421C-AA71-9474097A2188Q37831512-BACF5FA1-3307-43F2-BD47-41F40B970E4BQ37891338-5665566B-795C-47BE-8F62-80177C033743Q37939967-D008F162-7FFF-4738-808D-755601CCDA89Q37976436-E15199E2-E7A8-4945-A1BD-2F4F5A836AFBQ38209743-F6D6E5CB-680F-4595-B133-0F4D6FB5E07EQ38608263-839E1308-2378-42F4-BECE-5DFFA768BDECQ38794710-B539F5A5-8725-4295-B122-8AF985E7459FQ38795185-7D1B9E49-4A98-4002-88C5-F7205AB132CAQ38837546-573DA9E7-58EA-4F8F-8A0D-DCA87EDAA894Q38913871-7AED7313-0551-4431-BCD0-F242B44C4263Q38915488-16BB0D99-6DCA-4694-ABB1-A1D841FB8E52Q38931069-553418BA-729F-4DE8-A50A-212A660B7392Q39301322-DEDCC3AE-8B13-4707-B144-778D3C02696DQ39414448-8348120D-2FE7-4F88-9DF9-1D156C519E81Q39593858-1E8B4741-EEA1-4E33-BEB1-F217E2D96BB3Q40017027-22ED75E7-7CDA-47EB-8966-D3BDB1339B1EQ40113438-0C48E2B7-42FB-4FD4-A278-6D288348D20FQ40409072-A5C07FCA-68CD-474A-AB01-DAD95C1CB91DQ41260993-8F7B0ECC-EC2F-42C8-9FEA-F226F90B98E1Q42159867-214B6D94-F7C3-41E5-9DB3-39E3B0AC73A1Q43290674-6BE0AF0B-8330-44A8-9A6F-28CA525EEA12Q43903558-D8A3FAF1-5EB7-4DF8-8539-C11E69798FA7Q43963775-715F1A9E-2A6A-442B-9C28-5107DC7A6F91Q44772917-0CFD5354-4263-4BE1-8F34-6C4EE3847099Q44886690-ED39A9DD-013B-43BC-A3D1-89CF768AEBAEQ44931279-3946D5F6-BCDA-4140-B70D-122D69F30D1FQ45047450-DE80BFD5-C4BD-4E9E-9690-7600D3FAFC63Q45253881-015CBA1A-1935-4D2D-83FA-60839531A080Q46089916-19B68EFD-9E4C-48E5-8194-F2414C995C33Q46794974-F8029AEB-2665-49B7-9AA2-BDDCFE79C8FFQ46813937-FF1C2F5F-918E-40A2-8102-2C7E91C804FEQ46937731-B0FC03BE-4329-4A94-83C4-08AAEC36D6E3Q47172253-89BF8609-FA7D-4E4C-B219-1E0A2967F5BEQ47182893-89D87F85-AC42-45AC-A6C7-F1C7BEDC82C9Q47189713-12CB50E8-FB56-4AED-8996-2D833720ABBDQ47197520-B3C8CF52-0DF2-46A3-9920-357EE7D20E82
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Lisa M. Kaminskas
@ast
Lisa M. Kaminskas
@en
Lisa M. Kaminskas
@es
Lisa M. Kaminskas
@nl
Lisa M. Kaminskas
@sl
type
label
Lisa M. Kaminskas
@ast
Lisa M. Kaminskas
@en
Lisa M. Kaminskas
@es
Lisa M. Kaminskas
@nl
Lisa M. Kaminskas
@sl
prefLabel
Lisa M. Kaminskas
@ast
Lisa M. Kaminskas
@en
Lisa M. Kaminskas
@es
Lisa M. Kaminskas
@nl
Lisa M. Kaminskas
@sl
P106
P1153
6602912496
P21
P31
P496
0000-0003-4821-4262